Long-Term Debt: Sutro Bio (STRO)

Brandmark of Sutro Biopharma, Inc (STRO)

Sutro Biopharma, Inc. (STRO) relies on the creation of precise antibody conjugates to combat tumors using a cell-free synthesis method. The business implements robotic drug screening on a 24/7 basis, while the visualization of market value with the 0.00 metric demonstrates market dynamics. The company's success is driven by qualified executives with scientific expertise who prioritize data transparency and the development of strategic partnerships.

STRO (Sutro Bio) Company Long-Term Debt history from 07/04/2022 to 10/29/2026

Sutro Bio - analytical breakdowns and key metrics (STRO)

- current quotes and average value forecast:
Stock Quotes sutrobio.com|STRO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Sutro Biopharma|STRO - Total Company Value
- book capitalization data:
Net Assets per Single Share Sutro Biopharma|STRO - Company Book Value|Market-to-Book Ratio sutrobio.com|STRO - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Sutro Biopharma, Inc.|STRO - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Sutro Biopharma, Inc|STRO - Company Total Debt|Debt to Net Assets Ratio Sutro Biopharma|STRO - Company Long-Term Debts|Short-Term Debt Volume Sutro Biopharma|Quick Liquidity Indicator sutrobio.com
- net income and valuation multiples indicators:
STRO - Company Net Income
Fundamental company valuation:sutrobio.com
Core merchandise of Sutro Biopharma

Sutro Biopharma, Inc. (STRO) is scaling its cell-free protein synthesis platform through strategic alliances, which requires significant R&D capital expenditures. Monitoring the corporation's long-term loans and borrowings allows for an assessment of total liabilities with maturities exceeding one year, reflecting the balance between investments in technological breakthroughs and the company's financial stability amid interest rate volatility.

Who Sutro Biopharma, Inc. competes with

IBRX - Company Long-Term Liabilities|IMCR - Company Long-Term Debt|Long-Term Debt Janux Therapeutics Inc|Arcus Bio (RCUS) - Company Long-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Long-Term Debt|Company Long-Term Debt Tango Therapeutics|Long-Term Debt iovance.com IOVA|Company Long-Term Debts IMTX|Xencor Inc (XNCR) - Long-Term Indebtedness|Compass Bio - Company Long-Term Liabilities|Replimune Inc. (REPL) - Long-Term Debt|LYEL: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Long-Term Debts|CGEN - Long-Term Debt Volume|Company Long-Term Debt IO Biotech Corp|Company Long-Term Liabilities MiNK Therapeutics, Inc (INKT)|Company Long-Term Debt Werewolf Therapeutics (HOWL)|Company Long-Term Liabilities immixbio.com IMMX|ALX Oncology Holdings - Company Long-Term Liabilities|Company Long-Term Debts cuebiopharma.com CUE|PDSB - Company Long-Term Debt|SONN (Sonnet BioTherapeutics) - Company Long-Term Indebtedness|MAIA Biotechnology (MAIA) - Company Long-Term Debt|Long-Term Debt liminatuspharma.com (LIMN)|Company Long-Term Liabilities LVTX|NXTC - Long-Term Indebtedness|Company Long-Term Liabilities LPTX (Leap Therapeutics, Inc.)|Amount of Long-Term Liabilities INTS|Company Long-Term Debts SNSE (Sensei Biotherapeutics, Inc.)|Company Long-Term Loans and Borrowings TOVX|Gritstone Bio - Company Long-Term Debts|Long-Term Debt Kineta Inc|NexImmune Corp (NEXI) - Company Long-Term Debt|Turnstone Biologics Corp. - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts harpoontx.com